Telomir Pharmaceuticals, Inc.
TELO
$1.45
-$0.05-3.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 171.62% | -29.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 131.74% | -24.70% | |||
| Operating Income | -131.74% | 24.70% | |||
| Income Before Tax | -132.59% | 24.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -132.59% | 24.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -132.59% | 24.79% | |||
| EBIT | -131.74% | 24.70% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -130.74% | 25.08% | |||
| Normalized Basic EPS | -130.57% | 25.04% | |||
| EPS Diluted | -130.74% | 25.08% | |||
| Normalized Diluted EPS | -130.57% | 25.04% | |||
| Average Basic Shares Outstanding | 0.83% | 0.34% | |||
| Average Diluted Shares Outstanding | 0.83% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||